中国组织工程研究

中国组织工程研究 ›› 2011, Vol. 15 ›› Issue (24): 4477-4480.doi: 10.3969/j.issn.1673-8225.2011.24.026

• 组织构建细胞学实验 cytology experiments in tissue construction • 上一篇    下一篇

四氧嘧啶型糖尿病模型小鼠糖耐量和肝糖原与大豆胰蛋白酶抑制剂的干预

郭瑞华1，王慧丽2，翟义敏1，胡  艳1，金晓董1   

  1. 1华北煤炭医学院药学系，河北省唐山市  063000
    2 唐山妇幼医院药剂科，河北省唐山市  063000
  • 收稿日期:2010-12-26 修回日期:2011-01-30 出版日期:2011-06-11 发布日期:2011-06-11
  • 作者简介:郭瑞华，女，1951年生，河北省秦皇岛人，汉族，河北师范大学毕业，教授，硕士生导师，主要从事降糖中药有效成分及降糖机制的研究。 rhuag71@163. com
  • 基金资助:

    河北省科技厅科研项目(07276191)，课题名称：大豆胰蛋白酶抑制剂对糖尿病及其并发症活性的研究。

Effects of soybean trypsin inhibitor on glucose tolerance and hepatic glycogen in alloxan diabetic mice

Guo Rui-hua1, Wang Hui-li2, Zhai Yi-min1, Hu Yan1, Jin Xiao-dong1   

  1. 1Department of Pharmacy, North China Coal Medical College, Tangshan  063000, Hebei Province, China
    2Department of Pharmacy, Tangshan Women and Children Hospital, Tangshan  063000, Hebei Province, China
  • Received:2010-12-26 Revised:2011-01-30 Online:2011-06-11 Published:2011-06-11
  • About author:Guo Rui-hua, Professor, Master’s supervisor, Department of Pharmacy, North China Coal Medical College, Tangshan 063000, Hebei Province, China rhuag71@163.com
  • Supported by:

    the Project of Science and Technology Department of Hebei Province, No. 07276191*

PDF

380

被引次数

14

摘要：

背景：研究提示大豆胰蛋白酶抑制剂(soybean trypsin inhibitor，SBTI)对治疗糖尿病，调节胰岛素失调可能有一定效果。
目的：观察SBTI对四氧嘧啶糖尿病模型小鼠血糖、糖耐量及肝糖原的影响。
方法：采用腹腔注射四氧嘧啶方法制备小鼠糖尿病模型，将造模成功的32只小鼠随机等分为4组，另取正常8只小鼠作为对照组。造模后，SBTI-L、SBTI-H组每日分别灌胃0.27，0.80 mg/kg SBTI溶液，格列本脲组每日灌胃优降糖0.16 g/kg，模型组和对照组每日灌胃生理盐水，持续给药2周。给药第0，7，14天，采用葡萄糖氧化酶法测定小鼠空腹血糖和糖耐量，改良蒽酮法测定小鼠肝糖原含量。
结果与结论：与模型组比较，格列本脲组、SBTI-L组、SBTI-H组血糖明显下降(P < 0.05)，糖耐量升幅明显减小(P < 0.05)，肝糖原含量明显增加(P < 0.05)，且SBTI-L组、SBTI-H组较格列本脲组起效快，作用时间长，以SBTI-H组效果最明显。表明SBTI有明显的降血糖、改善糖耐量、提高肝糖原含量的作用。

关键词: 大豆胰蛋白酶抑制剂, 四氧嘧啶, 糖尿病, 动物模型, 改良蒽酮法, 糖耐量, 肝糖原

Abstract:

BACKGROUND: Previous studies found soybean trypsin inhibitor (SBTI) may have effect on treating diabetes mellitus and regulating insulin disturbance.
OBJECTIVE: To study the effects of SBTI on blood glucose, glucose tolerance, and hepatic glycogen in alloxan diabetic mice.
METHODS: Alloxan diabetic mice models were prepared by intraperitoneal injection of alloxan, and 32 mice with successful model preparation were randomly divided into 4 groups, additional 8 mice were served as control. After model preparation, mice in the SBTI-L and SBTI-H groups were lavaged with 0.27 and 0.80 mg/kg SBTI solution, those in the glibenclamide group was lavaged with 0.16 g/kg glibenclamide. Saline was lavaged in the model and control groups. The medication lasted for 2 weeks. The blood glucose and glucose tolerance of mice were measured by using glucose oxidase method, and the content of hepatic glycogen was determined by the improved anthrone method.
RESULTS AND CONCLUSION: Compared with the model group, the blood glucose of glibenclamide, SBTI-L, and SBTI-H groups was significantly decreased (P < 0.05), and the glucose tolerance rise lower (P < 0.05), but the hepatic glycogen increased obviously (P < 0.05). The SBTI-L and SBTI-H groups showed faster effect and longer effectiveness than the glibenclamide group, especially more manifest in the SBTI-H group. Experimental results show that SBTI can significantly decrease blood glucose, improve glucose tolerance, and increase the content of hepatic glycogen.

中图分类号: